SCHEMBL2333945

SCHEMBL2333945

COC(=O)C1(NS(=O)(=O)c2c(C)cc(OC)cc2C)CCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
MMP1 P03956 4/20 0.36
MMP13 P45452 4/20 0.36
CNR2 P34972 1/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ADAM17 P78536 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333346 0.78 ALDH1A1 (0.39) ALDH1A1FFAR4SMN1; SMN2MEN1TSHR
SCHEMBL13232724 0.77 ALDH1A1 (0.40) ALDH1A1FFAR4SMN1; SMN2MEN1TSHR
SCHEMBL643982 0.74 MMP1 (0.55) ALDH1A1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL7067100 0.70 USP2 (0.49) SMN1; SMN2TSHRLMNAHTTMMP1
SCHEMBL7964591 0.69 MAPT (0.38) ALDH1A1MEN1TSHRKMT2ALMNA
SCHEMBL1935802 0.69 ALDH1A1 (0.51) ALDH1A1FFAR4SMN1; SMN2MEN1TSHR
SCHEMBL27618200 0.69 MMP1 (0.46) ALDH1A1SMN1; SMN2HTTMMP1MMP13
SCHEMBL7949759 0.68 MAPT (0.40) ALDH1A1MEN1KMT2ACYP3A4HPGD
SCHEMBL7950104 0.68 MAPT (0.40) ALDH1A1MEN1KMT2ACYP3A4HPGD
SCHEMBL7958068 0.68 MAPT (0.40) ALDH1A1MEN1KMT2ACYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
EP-2356101-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2011-08-17 EP disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
WO-2010046109-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS ALDH1A1 2375/4885FFAR4 2980/4885SMN1; SMN2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.